The SVP – CMO of BioCryst (BCRX) is Selling Shares
Today, the SVP – CMO of BioCryst (BCRX), William P. Sheridan, sold shares of BCRX for $155.3K.
In addition to William P. Sheridan, 3 other BCRX executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, BioCryst has an average volume of 1.05M. The Company has a Price to Book ratio of 11.4178.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $13.50, reflecting a 91.2% upside.
In the last 30 days, insiders have sold $594.1K worth of BCRX shares and purchased $12.42K worth of BCRX shares. The insider sentiment on BioCryst has been negative according to 40 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.